Nilotinib bests imatinib in chronic myeloid leukemiaQuestions about tolerability and cost of treatment need answering before clinical practice should change How to tackle no-shows N.B. medical society names new executive director Wait times for diagnosis exceed accepted targets Study highlights postop transfusion risks Evidence mounts that liberal approach is no better than conservative, and may even increase morbidity and mortality Maternal cytokine regulation linked to autism Test results show timing of Epstein-Barr infection Dabigatran lowers deep vein clot risk Newer drug compares well with warfarin and does not require lab monitoring Natural products targeting diabetes vary in value While products in question seem safe, not all boast effectiveness. A new drug target for iron disorders? First Previous 3438 3439 3440
